Clintec has been presented with the Queens Award for Enterprise 2017, in the category of International Trade - by Lord Provost, Eva Bolander in her capacity as Lord Lieutenant. The award ceremony coincides with the company's continued expansion – with the official opening of an additional 4,327sq feet floor at Clintec’s Glasgow-based headquarters, with the additional space forming a fully dedicated center of excellence for clinical research and quality assurance capabilities.
The Queens Award, the highest business accolade that can be granted to any business operating within the UK, recognizes outstanding corporate achievement and more than 20 years of consistent business success.
Clintec, a premier global solutions provider for clinical research, has an impressive geographical footprint spanning the globe, providing a comprehensive global Functional Services platform for both the global and mid-market pharmaceutical segments, and also to smaller biotechnology companies who require comprehensive full-service solutions.
“We are honoured to have received the Queens Award for Enterprise for the second time – through which we celebrate 20 years of global success in clinical research,” Dr. Rabinder Buttar, Founder and CEO of Clintec, said. “Furthermore, we are delighted to mark today with the expansion of our clinical operational capabilities and HQ office space for the next stage of company growth.”
At the visit of the Lord Provost to Clintec’s HQ, Sophie Totten, Clintec’s first Master’s Graduate in International Clinical Research & Technology, was recognized for the Master’s Degree developed by Clintec jointly with Edinburgh Napier University. Totten trained as a CRA at Clintec and has been part of the team that has excelled in delivering clinical monitoring services to a Clintec client.